WO2016073983A3 - Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma - Google Patents

Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma Download PDF

Info

Publication number
WO2016073983A3
WO2016073983A3 PCT/US2015/059738 US2015059738W WO2016073983A3 WO 2016073983 A3 WO2016073983 A3 WO 2016073983A3 US 2015059738 W US2015059738 W US 2015059738W WO 2016073983 A3 WO2016073983 A3 WO 2016073983A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
hepatocellular carcinoma
inhibition
ornithine aminotransferase
gaba analogues
Prior art date
Application number
PCT/US2015/059738
Other languages
French (fr)
Other versions
WO2016073983A2 (en
Inventor
Richard B. Silverman
Yaron Ilan
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Priority to ES15856956T priority Critical patent/ES2882126T3/en
Priority to JP2017543338A priority patent/JP6867949B2/en
Priority to EP15856956.6A priority patent/EP3215144B1/en
Priority to AU2015342801A priority patent/AU2015342801A1/en
Priority to CA2966642A priority patent/CA2966642C/en
Priority to MX2017006022A priority patent/MX2017006022A/en
Publication of WO2016073983A2 publication Critical patent/WO2016073983A2/en
Publication of WO2016073983A3 publication Critical patent/WO2016073983A3/en
Priority to IL252042A priority patent/IL252042B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma.
PCT/US2015/059738 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma WO2016073983A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES15856956T ES2882126T3 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with GABA analogues for the treatment of hepatocellular carcinoma
JP2017543338A JP6867949B2 (en) 2014-11-07 2015-11-09 Inhibition of ornithine transaminase using GABA analogs for the treatment of hepatocellular carcinoma
EP15856956.6A EP3215144B1 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
AU2015342801A AU2015342801A1 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma
CA2966642A CA2966642C (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
MX2017006022A MX2017006022A (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma.
IL252042A IL252042B (en) 2014-11-07 2017-04-30 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076980P 2014-11-07 2014-11-07
US62/076,980 2014-11-07

Publications (2)

Publication Number Publication Date
WO2016073983A2 WO2016073983A2 (en) 2016-05-12
WO2016073983A3 true WO2016073983A3 (en) 2016-08-11

Family

ID=55910047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/059738 WO2016073983A2 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Country Status (9)

Country Link
US (1) US9603820B2 (en)
EP (1) EP3215144B1 (en)
JP (1) JP6867949B2 (en)
AU (1) AU2015342801A1 (en)
CA (1) CA2966642C (en)
ES (1) ES2882126T3 (en)
IL (1) IL252042B (en)
MX (1) MX2017006022A (en)
WO (1) WO2016073983A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519753A (en) * 2018-03-29 2021-08-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． (1S, 3S) -3-amino-4- (difluoromethylidene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylenyl) cyclopenta-1-ene in the treatment of eye disorders Use of -1-carboxylic acid
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
AU2019273028B2 (en) * 2018-05-25 2024-02-22 Northwestern University Process for the synthesis of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
CN112770739B (en) 2018-06-07 2023-12-12 奥维德医疗公司 Use of (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid and related compounds for the treatment of developmental disorders
US11203596B2 (en) 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) * 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
CN117203219A (en) * 2021-04-20 2023-12-08 拜斯科技术开发有限公司 Bicyclic peptide ligands specific for P-selectin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023364A1 (en) * 2006-08-21 2008-02-28 Hadasit Medical Research Services & Development Ltd. Inhibition of ornithine aminotransferase for the treatment of proliferative disorders
US7381748B1 (en) * 2002-07-19 2008-06-03 Northwestern University Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381748B1 (en) * 2002-07-19 2008-06-03 Northwestern University Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase
WO2008023364A1 (en) * 2006-08-21 2008-02-28 Hadasit Medical Research Services & Development Ltd. Inhibition of ornithine aminotransferase for the treatment of proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAUNE, G. ET AL.: "Interrelationships Between Ornithine, Glutamate, and GABA. II. Consequences of Inhibition of GABA-T and Ornithine Aminotransferase in Brain", NEUROCHEMICAL RESEARCH, vol. 13, no. 1, 1988, pages 69 - 75, XP009502735 *
LEE, H. ET AL.: "Ornithine Aminotransferase versus GABA Aminotransferase: Implications for the Design of New Anticancer Drugs", MEDICINAL RESEARCH REVIEWS, vol. 35, no. 2, 22 August 2014 (2014-08-22), pages 286 - 305, XP055439832 *
PAN, Y. ET AL.: "Conformationally-restricted vigabatrin analogs as irreversible and reversible inhibitors of delta-aminobutyric acid aminotransferase", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, no. 21, 11 September 2004 (2004-09-11), pages 5919 - 5725, XP004588174 *

Also Published As

Publication number Publication date
IL252042B (en) 2020-05-31
US20160128958A1 (en) 2016-05-12
EP3215144B1 (en) 2021-04-28
MX2017006022A (en) 2017-11-17
JP2017533964A (en) 2017-11-16
WO2016073983A2 (en) 2016-05-12
IL252042A0 (en) 2017-06-29
JP6867949B2 (en) 2021-05-12
EP3215144A4 (en) 2018-06-20
US9603820B2 (en) 2017-03-28
ES2882126T3 (en) 2021-12-01
CA2966642C (en) 2023-03-28
EP3215144A2 (en) 2017-09-13
CA2966642A1 (en) 2016-05-12
AU2015342801A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
WO2016073983A3 (en) Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
HK1247922A1 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
HK1246232A1 (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
IL273585A (en) Therapeutic methods relating to hsp90 inhibitors
WO2015101958A3 (en) Inhibitors of glutaminase
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
IL247589A0 (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
PH12017500747A1 (en) Heterocyclic compound
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
SA517381678B1 (en) Dihydropyrimidin-2-One Compounds and Medical Use Thereof
EP3302485A4 (en) Cerdulatinib for the treatment of b-cell malignancies
IL249502B (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
IL264950B1 (en) Combination therapies for the treatment of hepatocellular carcinoma
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
WO2016082807A3 (en) New use of itraconazole
WO2016038040A3 (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
SG11202006617RA (en) Combination therapies for the treatment of hepatocellular carcinoma
EP3624800A4 (en) Treatment of hepatocellular carcinoma
EP3334746A4 (en) Connexin 45 inhibition for therapy
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
AU2015903282A0 (en) Connexin 45 Inhibition for Therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15856956

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 252042

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2966642

Country of ref document: CA

Ref document number: 2017543338

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/006022

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2015856956

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015342801

Country of ref document: AU

Date of ref document: 20151109

Kind code of ref document: A